Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
ID Number 15-2014Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find out whether ramucirumab can help patients with liver cancer. Ramucirumab is an experimental drug because it is still being tested and not yet approved to treat liver cancer. However, the FDA has allowed the use of this drug for research.
Recruiting Patients: Yes